AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06601335
Drug: Placebo in combination with Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Following a predefined dose and date.
Trial: NCT05547542
Drug: CVL-354
RxNorm normalized name: CVL-231
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution/capsule
Trial: NCT05547542
Drug: [11C]-carfentanil
DrugBank: Carfentanil (DB01535)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection
Trial: NCT06668220
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine has become more popular as a caudal adjuvant in children; it is a highly selective α2 agonist with sedative and analgesic properties. Dexmedetomidine possesses anxiolytic, sedative, sympatholytic, and analgesic properties without respiratory depressant effects In addition; dexmedetomidine has the ability to reduce both the anesthetic and opioid analgesic requirements during the perioperative period.
Trial: NCT06668220
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
Trial: NCT06689527
Drug: Vamorolone
RxNorm normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 3 to 14: 6 mg/kg vamorolone once daily.
Trial: NCT06689527
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 and 14: Single doses of 2.5 mg midazolam
Trial: NCT06691360
Drug: AK137
RxNorm normalized name: Azelastine hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion, specified dose on specified days.
Trial: NCT04732468
Drug: hAd5-SFusion+ N-ETSD (Oral capsule)
RxNorm normalized name: (+/-)-N-methylephedrine
DrugBank: DL-Methylephedrine (DB11278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The hAd5-S-Fusion+N-ETSD Vaccine is a human adenovirus serotype 5 (hAd5) vector with E1/E2b/E3 deletions expressing SARS-CoV-2 viral antigen spike fusion protein and nucleocapsid with an enhanced T-cell stimulation domain.
Trial: NCT06596135
Drug: Setmelanotide
RxNorm normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open-label daily injections of setmelanotide
Trial: NCT06257420
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once weekly oral rapamycin
Trial: NCT05147493
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of administration: Intravenous (IV). Dose regimen: Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.
Trial: NCT05147493
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of administration: Subcutaneous (SC). Dose regimen: Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.
Trial: NCT05147493
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: per os (PO)/Intravenous (IV). Dose regimen: Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.
Trial: NCT04699877
Drug: Gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT05147493
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Route of administration: per os (PO). Dose regimen: Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards.
Trial: NCT04943757
Drug: Bendamustine Hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
Trial: NCT04943757
Drug: Cyclophosphamid
RxNorm normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
Trial: NCT05594875
Drug: SHR-1921
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive a single dose of SHR-1921 at dose level 1/2/3 on Day of each cycles
Trial: NCT05708690
Drug: Tranexamic Acid 100 MG/ML
RxNorm normalized name: tranexamic acid 100 MG/ML
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage
Trial: NCT06570538
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL/h of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.
Trial: NCT06571097
Drug: Levoﬂoxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g/day for 2 weeks
Trial: NCT05704088
Drug: Dapagliflozin tablet
RxNorm normalized name: Dapagliflozin Tablets
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: randomized control trial, study group will receive dapagliflozin tablets
Trial: NCT04714177
Drug: Edaravone Dexborneol
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage
Trial: NCT06062485
Drug: Surufatinib+Toripalimab+AG
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）
Trial: NCT05738317
Drug: Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adebrelimab is recommended to be administered with an infusion pump. The infusion pipeline is equipped with a 0.22-micron online filter membrane. Intravenous injection or bolus injection is not allowed. At the end of infusion, flush the infusion tube with sufficient 5% glucose or physiological saline, and do not share the same infusion tube with other drugs. In each treatment cycle, Adebrelimab should be given intravenously first.
Trial: NCT06317597
Drug: Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfate oral solution to 500ml and intake 12-14 hours before colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
Trial: NCT06317597
Drug: Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: OSS contained 17.5 g sodium sulfate, 3.13 g potassium sulfate, 1.6 g magnesium sulfate, and flavoring agents in an aqueous liquid form supplied in a 177 mL bottle. Dilute 177ml sodium, potassium, and magnesium sulfates oral solution to 500ml and intake 16-18 hours before the colonoscopy, followed by two doses of 500ml water or clear aqueous liquid within 2 hours; Repeat the procedure 6 hours before the colonoscopy.
Trial: NCT04635774
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 IU via four activations of an intranasal spray
Trial: NCT04635774
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four activations of an intranasal spray containing placebo (normal saline).
Trial: NCT06564714
Drug: Early baclofen Intervention
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen is initiated as soon as any sign of acute spasticity.~5 mg three times a day and is increased every 7 days by 5 mg per intake (up to a maximum 80 mg total per day) until achieving an optimal response, i.e. when spasticity is no longer problematic.
Trial: NCT05299580
Drug: dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg bid
Trial: NCT05299580
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib 2mg qd
Trial: NCT05341843
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sertraline at the intended dose of 50 mg twice daily for 8 weeks.
Trial: NCT05412979
Drug: ST-1891
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST-1891
Trial: NCT06637956
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received 1 mg of nitroglycerin intranasally two minutes prior to laryngoscopy and intubation
Trial: NCT04981145
Drug: Iguratimod Tablets
RxNorm normalized name: Iguratimod
DrugBank: Iguratimod (DB12233)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
Trial: NCT04981145
Drug: Hydroxychloroquine Sulfate Tablets
RxNorm normalized name: Hydroxychloroquine Sulfate Tablets
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
Trial: NCT05941429
Drug: Nano-Silver Fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSF is a varnish which has been introduced as experimental formulation . the laboratory synthesis of NSF was carried out in a nano techonolgy center .
Trial: NCT05941429
Drug: Silver diamine fluoride
RxNorm normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 38% silver diamine fluoride
Trial: NCT04588792
Drug: Nebulized Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide administered by nebulization through the ventilator circuit
Trial: NCT05838287
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be taking Pioglitazone tablets 1/day for 24 weeks.
Trial: NCT05713292
Drug: Pirfenidone Oral Product
RxNorm normalized name: pirfenidone Oral Product
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone 200mg tid for first week; subsequently, 400mg tid for 2 months
Trial: NCT05713292
Drug: Pirfenidone placebo
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone placebo
Trial: NCT06501976
Drug: Lurbinectedin
RxNorm normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.6 mg/m2 , Given IV, every 21 days
Trial: NCT06375811
Drug: Elagolix 200 MG
RxNorm normalized name: elagolix 200 MG
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix tablet
Trial: NCT06696794
Drug: Normal Saline (Placebo)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (Normal Saline) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
Trial: NCT04886271
Drug: HX009
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible participants will receive HX009 treatment at 5mg/Kg via IV infusion over 60-120 minutes, and the scheduled dosing cycle is once every 2 weeks.
Trial: NCT05352893
Drug: Imsidolimab high dose
RxNorm normalized name: high-density polyethylene
DrugBank: Imsidolimab (DB16658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT05352893
Drug: Imsidolimab low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Imsidolimab (DB16658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous
Trial: NCT05620134
Drug: JK08
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
Trial: NCT05620134
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immune checkpoint inhibitor
Trial: NCT05620134
Drug: Lenvatinib Pill
RxNorm normalized name: lenvatinib Pill
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Multi-kinase inhibitor
Trial: NCT06265415
Drug: Labetalol
RxNorm normalized name: Labetalol
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: it contains both selective, competitive, alpha1-adrenergic antagonism and non-selective, competitive, beta-adrenergic (B1 and B2) blocking activity in a single agent
Trial: NCT06265415
Drug: Nitroglycerine
RxNorm normalized name: Nitroglycerine
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a nitric oxide donor with low oral bioavailability and a very short half-life, has a potent venodilator effect in low doses and affects arterial tone at high doses
Trial: NCT06265415
Drug: Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dihydropyridine calcium channel blocker. Its main uses are as an antianginal and antihypertensive
Trial: NCT06124404
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After a loading dose of 0.08mg/kg, a maintaining dose of 0.1mg/kg/h is given
Trial: NCT06124404
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After a loading dose of 0.08mg/kg, a maintaining dose of 0.2mg/kg/h is given
Trial: NCT06124404
Drug: Remimazolam besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After a loading dose of 0.08mg/kg, a maintaining dose of 0.4mg/kg/h is given
Trial: NCT05881291
Drug: ciprofol
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1.
Trial: NCT05881291
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1.
Trial: NCT05185622
Drug: Vamorolone
RxNorm normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of vamorolone for 12 weeks.
Trial: NCT05227326
Drug: PCNA Inhibitor AOH1996
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05686980
Drug: ABBV-552
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06569485
Drug: Trilaciclib+R-CHOP
RxNorm normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Trilaciclib in DLBCL patients treated with R-CHOP.
Trial: NCT05405608
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hemodynamic stability in orthopedic surgeries
Trial: NCT05972785
Drug: RAS
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
Trial: NCT05972785
Drug: Other AHT
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with ATC code C02 will be categorised as other antihypertensives.
Trial: NCT06564740
Drug: Stem Cell
RxNorm normalized name: Stem cells, apheresis
DrugBank: Umbilical Cord Blood Hematopoietic Stem Cells (DB15723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC/kg.
Trial: NCT06114628
Drug: BTZ-043
RxNorm normalized name: BTZ-043
DrugBank: BTZ-043 (DB17737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dosage of 1000mg.
Trial: NCT06114628
Drug: Bedaquiline (B)
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral daily dosage of 400mg for the first 2 weeks, thereafter 100mg daily until end of treatment.
Trial: NCT06114628
Drug: Delamanid (D)
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Oral daily dosage of 300mg.
Trial: NCT06114628
Drug: Pretomanid (Pa)
RxNorm normalized name: pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral daily dosage of 200mg.
Trial: NCT06114628
Drug: Moxifloxacin (M)
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral daily dosage of 400mg.
Trial: NCT06114628
Drug: Linezolid (L)
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral daily dosage of 600mg for the first 8 weeks.
Trial: NCT06114628
Drug: Pyrazinamide (Z)
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral daily dosage of 1200mg-2000mg depending on weight.
Trial: NCT06114628
Drug: Rifampicin (R)
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral daily dosage of 450mg-750mg depending on weight.
Trial: NCT06114628
Drug: Isoniazid (H)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral daily dosage of 225mg-375mg depending on weight.
Trial: NCT06114628
Drug: Ethambutol (E)
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral daily dosage of 825mg-1375mg depending on weight.